We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red. The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The interactive Survival Scatter plot allows for the cutoff to be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Survival analysis". Under the Survival Scatter plot the p-score landscape is shown together with the difference in median between survival time for patients who have died with respect to high and low expression. This is intended to aid the user in exploring custom cutoffs.
Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off).
Based on the FPKM value of each gene, we classified the patients into two groups and examined their prognoses. In the analysis, we excluded genes with low expression, i.e., those with a median expression among samples less than FPKM 1. The prognosis of each group of patients was examined by Kaplan-Meier survival estimators, and the survival outcomes of the two groups were compared by log-rank tests. To choose the best FPKM cut-offs for grouping the patients most significantly, all FPKM values from the 20th to 80th percentiles were used to group the patients, significant differences in the survival outcomes of the groups were examined and the value yielding the lowest log-rank P value is selected.
: 82.24
Median expression: N/A
Median follow up time: N/A P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A 5-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A 5-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average FPKM
107.2
Number of samples
64
Samples
Sample
Description
FPKM
TCGA-KN-8421-01A
48 years, female, white, stage:ii, alive, 2674 days
172.7
TCGA-KN-8418-01A
41 years, female, white, stage:ii, alive, 3935 days
157.7
TCGA-KL-8339-01A
67 years, male, white, stage:iv, dead, 855 days
152.6
TCGA-KL-8328-01A
60 years, male, white, stage:ii, alive, 3127 days
151.5
TCGA-KO-8411-01A
58 years, male, white, stage:i, alive, 3958 days
148.0
TCGA-KM-8439-01A
30 years, male, white, stage:i, alive, 708 days
147.1
TCGA-KN-8432-01A
86 years, female, white, stage:ii, alive, 76 days
146.9
TCGA-KL-8337-01A
26 years, male, black or african american, stage:ii, alive, 1364 days
142.2
TCGA-KN-8424-01A
42 years, female, white, stage:i, alive, 1983 days
141.7
TCGA-KM-8438-01A
45 years, female, white, stage:ii, alive, 4622 days
140.9
TCGA-KO-8405-01A
29 years, male, white, stage:iii, alive, 3056 days
138.2
TCGA-KL-8341-01A
41 years, male, asian, stage:iv, dead, 754 days
137.4
TCGA-KN-8431-01A
35 years, female, stage:ii, alive, 588 days
136.8
TCGA-KN-8429-01A
38 years, female, white, stage:iii, alive, 2650 days
136.3
TCGA-KL-8330-01A
44 years, female, black or african american, stage:ii, alive, 3304 days
136.3
TCGA-KO-8417-01A
30 years, female, white, stage:i, alive, 2815 days
136.0
TCGA-KL-8336-01A
51 years, female, white, stage:iv, dead, 920 days
134.7
TCGA-KL-8340-01A
34 years, male, white, stage:ii, alive, 2024 days
133.2
TCGA-KL-8331-01A
48 years, female, white, stage:ii, alive, 3010 days
129.4
TCGA-KL-8344-01A
51 years, male, white, stage:iii, alive, 876 days
128.9
TCGA-KL-8335-01A
68 years, male, white, stage:iii, alive, 2815 days
127.8
TCGA-KM-8440-01A
37 years, male, black or african american, stage:iii, alive, 1366 days
127.2
TCGA-KM-8442-01A
38 years, male, stage:ii, alive, 1437 days
126.1
TCGA-KO-8414-01A
50 years, female, white, stage:ii, alive, 3212 days
123.8
TCGA-KL-8334-01A
37 years, female, white, stage:iii, alive, 2949 days
122.8
TCGA-KL-8323-01A
57 years, female, white, stage:iii, dead, 1158 days
121.9
TCGA-KL-8329-01A
57 years, female, asian, stage:i, alive, 2752 days
120.8
TCGA-KO-8404-01A
78 years, male, white, stage:iv, dead, 325 days
118.8
TCGA-KL-8345-01A
75 years, male, white, stage:iii, alive, 1665 days
113.8
TCGA-KN-8435-01A
59 years, male, white, stage:ii, alive, 3498 days
113.2
TCGA-KM-8443-01A
58 years, male, white, stage:ii, alive, 1520 days
111.1
TCGA-KN-8437-01A
42 years, female, white, stage:i, alive, 3068 days
110.8
TCGA-KM-8441-01A
61 years, female, white, stage:i, alive, 876 days
110.0
TCGA-KO-8409-01A
69 years, male, white, stage:ii, alive, 3180 days
107.2
TCGA-KL-8342-01A
45 years, female, white, stage:ii, alive, 2248 days
105.4
TCGA-KL-8338-01A
51 years, male, white, stage:iii, alive, 2633 days
105.3
TCGA-KL-8333-01A
69 years, male, white, stage:ii, alive, 2991 days
102.7
TCGA-KO-8403-01A
49 years, male, white, stage:i, alive, 3208 days
101.4
TCGA-KM-8476-01A
47 years, male, white, stage:i, alive, 3745 days
101.3
TCGA-KO-8407-01A
42 years, male, white, stage:ii, alive, 2820 days
100.5
TCGA-KN-8419-01A
43 years, male, black or african american, stage:ii, alive, 714 days
97.9
TCGA-KN-8425-01A
53 years, male, white, stage:i, alive, 3179 days
97.6
TCGA-KM-8477-01A
56 years, male, white, stage:i, alive, 1553 days
93.0
TCGA-KN-8434-01A
65 years, female, white, stage:ii, alive, 1797 days
91.1
TCGA-KO-8406-01A
17 years, female, white, stage:i, alive, 3145 days
90.9
TCGA-KL-8326-01A
69 years, male, white, stage:iii, alive, 3322 days
90.7
TCGA-KM-8639-01A
67 years, male, white, stage:i, alive, 953 days
90.4
TCGA-KO-8413-01A
46 years, male, white, stage:i, alive, 3038 days
85.0
TCGA-KO-8416-01A
41 years, male, white, stage:iii, alive, 2752 days
82.7
TCGA-KN-8428-01A
71 years, male, white, stage:ii, dead, 1590 days
81.8
TCGA-KO-8408-01A
47 years, male, white, stage:iii, dead, 507 days
80.2
TCGA-KN-8436-01A
63 years, male, white, stage:ii, alive, 1288 days
72.0
TCGA-KO-8415-01A
44 years, female, white, stage:i, alive, 2939 days
69.7
TCGA-KN-8426-01A
50 years, male, white, stage:iv, alive, 108 days
65.6
TCGA-KL-8324-01A
67 years, female, white, stage:ii, alive, 4676 days
64.8
TCGA-KN-8427-01A
54 years, male, white, stage:iv, alive, 30 days
63.9
TCGA-KN-8423-01A
44 years, male, white, stage:i, alive, 788 days
60.3
TCGA-KN-8433-01A
46 years, female, white, stage:iii, alive, 341 days
56.7
TCGA-KL-8343-01A
72 years, male, white, stage:iii, dead, 2172 days
56.3
TCGA-KL-8327-01A
46 years, female, white, stage:i, alive, 4169 days
56.0
TCGA-KL-8325-01A
56 years, female, white, stage:ii, dead, 725 days
53.9
TCGA-KO-8410-01A
74 years, female, white, stage:i, alive, 3136 days
The Human Protein Atlas project is funded
MENU
